John Berriman was appointed to the Board in July 2011 and became Chairman in March 2015.
He is currently also chairman of Confo Therapeutics NV, Autifony Therapeutics Ltd and Depixus SAS, and Deputy Chairman (non-executive) of Autolus Therapeutics Limited.
He is past Chairman of Heptares Therapeutics Ltd (sold to Sosei in February 2015) and Algeta ASA (sold to Bayer AG in 2014) and was a director of Micromet Inc. until its sale to Amgen in 2012. He spent 14 years with Celltech Group plc and was a member of its Board when it listed on the London Stock Exchange in 1994. Previously he was a director of Abingworth Management, an international healthcare venture capital firm. He has a degree in Chemical Engineering from the University of Cambridge and a Masters degree from the London Business School.
Olav Hellebø was appointed to the Board in September 2014.
Prior to ReNeuron, he held the role of CEO at Clavis Pharma ASA, a Norwegian, oncology-focused, listed biotechnology company. He joined Clavis from UCB where he built the global organisation responsible for the successful registration and launch of the anti-TNF Cimzia®. Mr Hellebø was COO of Novartis UK and prior to that held a series of senior roles at Schering Plough, including US marketing director for Claritin and head of the Biotech Oncology Business Unit in the USA.
Olav has an MBA from the IESE Business School in Spain and a Bachelor of Business Administration from Hofstra University, USA.
Michael Hunt joined ReNeuron in 2001. Between 2005 and 2014 he served as its CEO, leading the business through its early development to its current position as one of the global, clinical-stage leaders in the regenerative medicine field. He was appointed Chief Financial Officer in 2014.
He sits on the Board and Executive Committee of the US-based Alliance for Regenerative Medicine (ARM) and is a founding member and co-chair of ARM’s European Section. He sits on the UK BioIndustry Association’s Cell & Gene Therapy Advisory Committee and its Finance and Tax Advisory Committee and is a member of the Cell & Gene Therapy Catapult’s Advisory Panel.
Prior to ReNeuron, he spent six years at Biocompatibles International plc (sold to BTG plc) where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc.
He read economics at University College London and qualified as a chartered accountant with Ernst & Young
Simon Cartmell OBE was appointed to the Board in July 2011.
He is an experienced non-executive director currently chairing OssDsign AB, Oviva AG and Ieso Digital Health Ltd. He is also Non-Executive Director of BoneSupport Holding AB and is active in charitable educational activities through the Worshipful Company of Haberdashers.
As CEO of ApaTech Ltd, he built a world leader in orthobiologics and led its sale to Baxter International Inc in March 2010. Prior to ApaTech he was CEO of Celltech Pharmaceuticals and a director of Celltech Group plc before which he was COO of Vanguard Medica plc. His early career was spent at Glaxo plc in multiple senior UK and global commercial strategy, product development, supply chain, marketing, sales and business development roles. Most recently he has served as an Operating Partner for Imperial Innovations plc, latterly IP Group plc after its acquisition, a leading UK bioscience venture capital firm
He is a Medical Microbiology graduate from Manchester University and an alumnus of the London Business School Sloan Fellowship Programme.
Dr Tim Corn was appointed to the Board in June 2012.
He serves as non-executive director on the Board of Neurocentrx Pharma Ltd, as Chairman of the Board of Trustees of The Neuro Foundation and as Chief Medical Officer of Izana Bioscience.
He was formerly Chief Medical Officer at EUSA Pharma International, a division of Jazz Pharmaceuticals, at EUSA Pharma Inc and at Zeneus Pharma, as well as Non-executive Director at Circassia Pharmaceuticals plc and HRA Pharma.
He has held senior medical, clinical and regulatory positions in both big and small pharma as well as in the UK regulatory agency and has played a key role in more than 20 regulatory approvals in the USA and Europe for products in the fields of neurology and oncology.
Dr. Corn qualified in medicine at King’s College Hospital, London after gaining a Master’s degree in biochemistry from Imperial College. He became consultant and senior lecturer in neuropsychiatry at the Institute of Psychiatry, London and is author of more than forty scientific publications.
He is a Fellow of both the Faculty of Pharmaceutical Medicine in 1996 and the Royal College of Psychiatrists
Dr Claudia D’Augusta was appointed to the Board in September 2017.
She is the Chief Financial Officer of VectivBio AG, a global biotechnology company created in July 2019 as a spin-out of Therachon AG, recently acquired by Pfizer for up to $810 million.
She has over 20 years’ experience in corporate finance, capital markets and M&A. Before joining Therachon in January 2019, Dr D’Augusta was CFO, then General Manager at Tigenix (now Takeda) where she led the company’s IPO on NASDAQ in 2016. She also served as CFO of Cellerix and led its merger with Tigenix. Dr D’Augusta was also finance director of Aquanima (Santander Group). Previous experience includes roles in corporate finance and M&A at Deloitte & Touche in Milan and Apax Partners in Madrid.
Dr D’Augusta holds a degree in Economics and a Ph.D. in Business Administration from the University of Bocconi, Italy.
Professor Sir Chris Evans OBE was appointed to the Board in August 2013.
He was the founder of Chiroscience, Celsis, Biovex, Merlin Biosciences, Vectura, Piramed, Excalibur Group, Arthurian Life Sciences, Arix Bioscience plc and Proton Partners. He is also currently Founder and Chairman of Ellipses Pharma, a new cancer medicines company.
He has built over 50 medical companies from scratch, many from his own ideas and inventions, and floated 20 new medical businesses on stock markets in six different countries. He has created companies worth over $7 billion employing over 4,000 scientists, built hundreds of complex medical laboratories and facilities around the world and positively impacted many millions of lives with his work. He has also raised $2 billion for cancer research projects. He has received numerous prestigious awards and medals for his work and was knighted in the year 2000.
Dr Mike Owen was appointed to the Board in December 2015.
He currently serves as a director of Zealand Pharma, Ossianix Inc. (chairman), Avacta plc, GammaDelta Therapeutics and is a member of the scientific advisory board at Avacta.
His career in biotech, the pharmaceutical industry and academia spans almost 40 years. He was formerly Senior vice president for biopharmaceuticals research at GlaxoSmithKline and was also a founder and chief scientific officer of Kymab Ltd, an antibody based biotech company. He has previously served as a director for BliNK Biomedical SAS. For many years held a research position at the Imperial Cancer Research Fund (now CR-UK) and he has previously served on the scientific advisory board of the CRT Pioneer Fund LP.
He is a Fellow of the Academy of Medical Sciences and a member of the European Molecular Biology Organisation.